8-K
filed September 7, 2023, 7:59 PM ET
ticker LCTX
CIK 0000876343
other material
confidence high
sentiment neutral
materiality 0.55
LCTX shareholders approve share increase and equity plan amendment at annual meeting
Lineage Cell Therapeutics, Inc.
- Authorized common shares increased from 250M to 450M via articles amendment.
- Equity incentive plan share pool increased by 19.5M shares (to 2021 Plan).
- All nine director nominees elected; Angus C. Russell received ~19.6M withheld votes.
- Ratification of WithumSmithBrown as auditor for FY2023 approved (118.5M for).
- Advisory say-on-pay approved with 70.3M votes for; future votes every year.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lineage Cell Therapeutics, Inc. shareholders approved Election of nine nominees to the board of directors at the 2023-09-06 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-09-06
Exact text from the filing
Proposal 1. The Company’s shareholders elected the nine nominees named below to the Company’s board of directors to hold office until the Company’s 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lineage Cell Therapeutics, Inc. shareholders approved Approval of amendment to 2021 Equity Incentive Plan to increase shares by 19,500,000 at the 2023-09-06 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-09-06
Exact text from the filing
Proposal 5. The Company’s shareholders approved the EIP Amendment by the votes set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lineage Cell Therapeutics, Inc. shareholders approved Advisory vote on frequency of holding advisory vote on executive compensation at the 2023-09-06 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-09-06
Exact text from the filing
Proposal 4. The Company’s shareholders voted as follows with respect to the preferred frequency of holding an advisory vote on the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lineage Cell Therapeutics, Inc. shareholders approved Ratification of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year 2023 at the 2023-09-06 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-09-06
Exact text from the filing
Proposal 2. The Company’s shareholders ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, by the votes set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lineage Cell Therapeutics, Inc. shareholders approved Amendment to restated articles of incorporation to increase authorized common shares from 250,000,000 to 450,000,000 at the 2023-09-06 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-09-06
Exact text from the filing
Proposal 6. The Company’s shareholders approved an amendment to the Company’s restated articles of incorporation to increase the number of authorized common shares from 250,000,000 to 450,000,000 by the votes set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lineage Cell Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-09-06 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-09-06
Exact text from the filing
Proposal 3. The Company’s shareholders approved, on an advisory and non-binding basis, the compensation paid to the Company’s named executive officers, as set forth in the Proxy Statement, by the votes set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lineage Cell Therapeutics, Inc. shareholders approved Adjournment of Annual Meeting to solicit additional proxies if necessary for Proposal 6 at the 2023-09-06 meeting.
- Outcome
- passed
- Meeting
- 2023-09-06
Exact text from the filing
Proposal 7. The Company’s shareholders approved the adjournment of the Annual Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 6 in the event there are not sufficient votes to approve Proposal 6 by the votes set forth below.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.